<DOC>
	<DOCNO>NCT01980888</DOCNO>
	<brief_summary>This study evaluate effect addition idelalisib bendamustine rituximab minimal residual disease ( MRD ) evaluate progression-free survival ( PFS ) participants previously untreated chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Efficacy Safety Idelalisib Combination With Bendamustine Rituximab Subjects With Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Documented diagnosis Bcell CLL , diagnosis establish accord International Workshop Chronic Lymphocytic Leukemia ( IWCLL ) No prior therapy CLL corticosteroid disease complication CLL warrant treatment Presence measurable lymphadenopathy Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 Known histological transformation CLL aggressive lymphoma ( ie , Richter transformation ) Known presence myelodysplastic syndrome Evidence ongoing systemic bacterial , fungal , viral infection time randomization Ongoing liver injury History noninfectious pneumonitis Ongoing inflammatory bowel disease History prior allogeneic bone marrow progenitor cell solid organ transplantation Ongoing immunosuppressive therapy corticosteroid Received last dose study drug another therapeutic clinical trial within 30 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>